Drug Trial Radar · NCT04398329
Dose-Escalation Study of HTX-034 Following Bunionectomy
Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
May 8, 2020
Primary completion
Jul 15, 2021
Study completion Jul 15, 2021
Sponsor
- Lead sponsor
- Heron TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase 1b/2, randomized, blinded, active-controlled study. Phase 1b evaluated escalating doses of HTX-034 compared with bupivacaine HCl. Phase 2 was a dose-expansion phase to evaluate additional subjects treated with the HTX-034 dose selected based on Phase 1b, compared with bupivacaine HCl.
Conditions
- Bunions
- Postoperative Pain
Interventions
HTX-034 low doseDrug
HTX-034 (bupivacaine/aprepitant/meloxicam) fixed dose: 21.7 mg/4.3 mg/0.6 mg
HTX-034 high doseDrug
HTX-034 (bupivacaine/aprepitant/meloxicam) individualized dose: 30.6 mg/6.1 mg/0.9 mg to 51.5 mg/10.3 mg/1.5 mg
Luer lock applicatorDevice
Applicator for instillation
Bupivacaine HClDrug
Bupivacaine HCl 50 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of TEAEs in Phases 1b/2Time frame: 42 days
- AUC0-72 of Pain ScoresTime frame: through 72 hours
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Arizona Research Center
Phoenix, Arizona
First Surgical Hospital
Bellaire, Texas
Endeavor Clinical Trials, LLC
San Antonio, Texas
JBR Clinical Research
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.